Table 5.
Results of the PRISMA checklist.
| Items | Liu et al., 2012 (China) [26] | Yu et al., 2013 (China) [27] | Zhang et al., 2013 (China) [28] | Qian, 2013 (China) [29] | Guo et al., 2013 (China) [30] | Zhang et al., 2014 (China) [31] | Zhang et al., 2017 (China) [32] | Zhu and Ding, 2018 (China) [33] | Han et al., 2019 (China) [34] | Lee et al., 2009 (South Korea) [35] | Li et al., 2014 (China) [36] | Zhao et al., 2015 (China) [37] | Chen et al., 2018 (China) [38] | Zhang et al., 2022 (China) [39] | Number of yes and partially yes(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1. Title | Y | N | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 100% |
| Q2. Structured summary | PY | PY | PY | PY | PY | PY | PY | PY | PY | PY | PY | PY | PY | PY | 100% |
| Q3. Rationale | Y | Y | Y | Y | PY | Y | Y | PY | Y | Y | Y | Y | Y | Y | 100% |
| Q4. Objectives | PY | PY | PY | PY | PY | PY | PY | PY | PY | PY | Y | Y | Y | Y | 100% |
| Q5. Protocol and registration | N | N | N | N | N | N | N | N | N | N | N | N | Y | Y | 14% |
| Q6. Eligibility criteria | PY | Y | Y | Y | Y | Y | Y | PY | Y | Y | Y | Y | Y | Y | 100% |
| Q7. Information sources | PY | PY | PY | PY | PY | PY | PY | PY | PY | Y | Y | Y | Y | Y | 100% |
| Q8. Search | N | N | N | N | N | N | N | N | N | N | N | Y | PY | Y | 21% |
| Q9. Study selection | N | PY | PY | N | N | PY | PY | N | PY | N | PY | PY | PY | PY | 64% |
| Q10. Data collection process | PY | PY | PY | PY | PY | N | PY | N | N | PY | PY | PY | PY | PY | 79% |
| Q11. Data items | N | PY | PY | N | PY | N | PY | N | N | PY | PY | PY | PY | PY | 64% |
| Q12. Risk of bias in individual studies | PY | PY | PY | PY | PY | PY | PY | PY | PY | PY | PY | PY | PY | PY | 100% |
| Q13. Summary measures | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 100% |
| Q14. Synthesis of results | Y | Y | Y | Y | Y | Y | Y | Y | Y | PY | Y | Y | Y | Y | 100% |
| Q15. Risk of bias across studies | N | PY | N | N | N | N | PY | PY | N | N | Y | N | Y | Y | 43% |
| Q16. Additional analyses | N | N | PY | N | N | N | PY | PY | N | N | Y | Y | Y | Y | 50% |
| Q17. Study selection | PY | PY | PY | PY | PY | PY | Y | PY | PY | Y | Y | Y | Y | Y | 100% |
| Q18. Study characteristics | PY | Y | Y | N | N | Y | Y | PY | Y | Y | Y | Y | Y | Y | 86% |
| Q19. Risk of bias within studies | PY | PY | PY | PY | N | PY | PY | PY | PY | PY | PY | Y | Y | Y | 93% |
| Q20. Results of individual studies | Y | Y | Y | PY | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 100% |
| Q21. Synthesis of results | PY | PY | PY | PY | PY | PY | Y | PY | PY | Y | Y | Y | Y | Y | 100% |
| Q22. Risk of bias across studies | N | PY | N | N | PY | N | PY | PY | PY | N | N | N | Y | Y | 50% |
| Q23. Additional analysis | N | N | PY | N | N | N | PY | PY | N | N | Y | Y | Y | Y | 50% |
| Q24. Summary of evidence | N | N | N | N | N | N | N | N | N | N | N | N | N | N | 0% |
| Q25. Limitations | PY | PY | PY | Y | N | Y | Y | PY | Y | PY | Y | Y | Y | Y | 93% |
| Q26. Conclusions | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 100% |
| Q27. Funding | PY | N | PY | N | PY | PY | PY | PY | PY | PY | Y | Y | PY | Y | 86% |
Note: Y: yes; N: no; PY: partial yes.